KYNAM CAPITAL MANAGEMENT LP
Q3 2024 Form 13-F
PRINCETON, NEW JERSEY
CIK 0001907884
· CRD 314368
· SEC-registered investment adviser
$1.3B Reported Value Total
KYNAM CAPITAL MANAGEMENT, LP reports 5 total accounts under management (AUM). There are 5 discretionary accounts valued at $1,833,940,841, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered
Discretionary Manager
Private funds (Form ADV)
1 fund
· $2.4B gross asset value
Hedge Fund: $2.4B
Source: Form ADV filed 2026-04-10
Reported value
$1.3B
Quarter over quarter
+15.4%
Holdings
24
Top-10 concentration
81.5%
Key People
Form ADV owners & control persons
Yue "nmn" Tang
LIMITED PARTNER
Jared Joseph Keller
CHIEF OPERATING OFFICER, CHIEF COMPLIANCE OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2024 13F record
Q3 2024 13F filing summary
| Period of report | September 30, 2024 |
|---|---|
| Filed | November 14, 2024 |
| Form | 13F-HR |
| Reported value | $1.3B |
| Positions | 24 |
| Change in reported value | +0.6% |
| New positions | 2 |
| Exited positions | 0 |
| Position turnover | 8.3% |
| Top-10 concentration | 81.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q3 2026 13F
Filed Nov 16, 2026
|
34 | $1.8B |
|
Q2 2026 13F
Filed Aug 14, 2026
|
32 | $1.8B |
|
Q1 2026 13F
Filed May 15, 2026
|
36 | $1.6B |
|
Q4 2025 13F
Filed Feb 17, 2026
|
35 | $1.6B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
35 | $1.3B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
31 | $928.8M |
|
Q1 2025 13F
Filed May 15, 2025
|
31 | $1.2B |
|
Q4 2024 13F
Filed Feb 14, 2025
|
29 | $1.7B |
|
Q3 2024 13F
Filed Nov 14, 2024
|
24 | $1.3B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
22 | $1.3B |
|
Q1 2024 13F
Filed May 15, 2024
|
21 | $955.5M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
23 | $902.6M |
|
Q3 2023 13F
Filed Nov 14, 2023
|
27 | $611.4M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
23 | $727.1M |
|
Q1 2023 13F
Filed May 15, 2023
|
34 | $774.6M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
31 | $651.9M |
|
Q3 2022 13F
Filed Nov 14, 2022
|
33 | $474.6M |
|
Q2 2022 13F
Filed Aug 15, 2022
|
31 | $391.6M |
|
Q1 2022 13F
Filed May 13, 2022
|
31 | $308.3M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
30 | $187.1M |
Top 20 holdings · Q3 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | NTRA NATERA INC | $259.3M | 19.88% |
| 2 | PCVX VAXCYTE INC | $118.8M | 9.1% |
| 3 | CLDX CELLDEX THERAPEUTICS INC NEW | $117.6M | 9.01% |
| 4 | SNDX SYNDAX PHARMACEUTICALS INC | $112.5M | 8.62% |
| 5 | COGT COGENT BIOSCIENCES INC | $99.8M | 7.65% |
| 6 | DVAX DYNAVAX TECHNOLOGIES CORP | $92.8M | 7.12% |
| 7 | VERA VERA THERAPEUTICS INC | $69.7M | 5.34% |
| 8 | BCRX BIOCRYST PHARMACEUTICALS INC | $69.0M | 5.29% |
| 9 | CGON CG ONCOLOGY INC | $66.8M | 5.12% |
| 10 | VRDN VIRIDIAN THERAPEUTICS INC | $57.1M | 4.38% |
| 11 | WVE WAVE LIFE SCIENCES LTD | $40.2M | 3.08% |
| 12 | BEAM BEAM THERAPEUTICS INC | $31.9M | 2.45% |
| 13 | TSVT 2SEVENTY BIO INC | $28.1M | 2.15% |
| 14 | LQDA LIQUIDIA CORPORATION | $22.7M | 1.74% |
| 15 | PTGX PROTAGONIST THERAPEUTICS INC | $20.5M | 1.57% |
| 16 | TVTX TRAVERE THERAPEUTICS INC | $19.2M | 1.47% |
| 17 | IRWD IRONWOOD PHARMACEUTICALS INC | $15.2M | 1.16% |
| 18 | VRTX P VERTEX PHARMACEUTICALS INC | $14.0M | 1.07% |
| 19 | ENGN ENGENE HOLDINGS INC | $11.5M | 0.88% |
| 20 | TYRA TYRA BIOSCIENCES INC | $11.0M | 0.84% |
Values as reported on the Q3 2024 Form 13F. Every position is in the holdings table below.